<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE patent-application-publication SYSTEM "pap-v16-2002-01-01.dtd" [
<!ENTITY US20030004335A1-20030102-C00001.CDX SYSTEM "US20030004335A1-20030102-C00001.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00001.MOL SYSTEM "US20030004335A1-20030102-C00001.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00001.TIF SYSTEM "US20030004335A1-20030102-C00001.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00002.CDX SYSTEM "US20030004335A1-20030102-C00002.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00002.MOL SYSTEM "US20030004335A1-20030102-C00002.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00002.TIF SYSTEM "US20030004335A1-20030102-C00002.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00003.CDX SYSTEM "US20030004335A1-20030102-C00003.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00003.MOL SYSTEM "US20030004335A1-20030102-C00003.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00003.TIF SYSTEM "US20030004335A1-20030102-C00003.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00004.CDX SYSTEM "US20030004335A1-20030102-C00004.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00004.MOL SYSTEM "US20030004335A1-20030102-C00004.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00004.TIF SYSTEM "US20030004335A1-20030102-C00004.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00005.CDX SYSTEM "US20030004335A1-20030102-C00005.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00005.MOL SYSTEM "US20030004335A1-20030102-C00005.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00005.TIF SYSTEM "US20030004335A1-20030102-C00005.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00006.CDX SYSTEM "US20030004335A1-20030102-C00006.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00006.MOL SYSTEM "US20030004335A1-20030102-C00006.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00006.TIF SYSTEM "US20030004335A1-20030102-C00006.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00007.CDX SYSTEM "US20030004335A1-20030102-C00007.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00007.MOL SYSTEM "US20030004335A1-20030102-C00007.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00007.TIF SYSTEM "US20030004335A1-20030102-C00007.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00008.CDX SYSTEM "US20030004335A1-20030102-C00008.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00008.MOL SYSTEM "US20030004335A1-20030102-C00008.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00008.TIF SYSTEM "US20030004335A1-20030102-C00008.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00009.CDX SYSTEM "US20030004335A1-20030102-C00009.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00009.MOL SYSTEM "US20030004335A1-20030102-C00009.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00009.TIF SYSTEM "US20030004335A1-20030102-C00009.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00010.CDX SYSTEM "US20030004335A1-20030102-C00010.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00010.MOL SYSTEM "US20030004335A1-20030102-C00010.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00010.TIF SYSTEM "US20030004335A1-20030102-C00010.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00011.CDX SYSTEM "US20030004335A1-20030102-C00011.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00011.MOL SYSTEM "US20030004335A1-20030102-C00011.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00011.TIF SYSTEM "US20030004335A1-20030102-C00011.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00012.CDX SYSTEM "US20030004335A1-20030102-C00012.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00012.MOL SYSTEM "US20030004335A1-20030102-C00012.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00012.TIF SYSTEM "US20030004335A1-20030102-C00012.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00013.CDX SYSTEM "US20030004335A1-20030102-C00013.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00013.MOL SYSTEM "US20030004335A1-20030102-C00013.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00013.TIF SYSTEM "US20030004335A1-20030102-C00013.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00014.CDX SYSTEM "US20030004335A1-20030102-C00014.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00014.MOL SYSTEM "US20030004335A1-20030102-C00014.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00014.TIF SYSTEM "US20030004335A1-20030102-C00014.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00015.CDX SYSTEM "US20030004335A1-20030102-C00015.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00015.MOL SYSTEM "US20030004335A1-20030102-C00015.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00015.TIF SYSTEM "US20030004335A1-20030102-C00015.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00016.CDX SYSTEM "US20030004335A1-20030102-C00016.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00016.MOL SYSTEM "US20030004335A1-20030102-C00016.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00016.TIF SYSTEM "US20030004335A1-20030102-C00016.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00017.CDX SYSTEM "US20030004335A1-20030102-C00017.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00017.MOL SYSTEM "US20030004335A1-20030102-C00017.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00017.TIF SYSTEM "US20030004335A1-20030102-C00017.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00018.CDX SYSTEM "US20030004335A1-20030102-C00018.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00018.MOL SYSTEM "US20030004335A1-20030102-C00018.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00018.TIF SYSTEM "US20030004335A1-20030102-C00018.TIF" NDATA TIF>
<!ENTITY US20030004335A1-20030102-C00019.CDX SYSTEM "US20030004335A1-20030102-C00019.CDX" NDATA CDX>
<!ENTITY US20030004335A1-20030102-C00019.MOL SYSTEM "US20030004335A1-20030102-C00019.MOL" NDATA MOL>
<!ENTITY US20030004335A1-20030102-C00019.TIF SYSTEM "US20030004335A1-20030102-C00019.TIF" NDATA TIF>
]>
<patent-application-publication>
<subdoc-bibliographic-information>
<document-id>
<doc-number>20030004335</doc-number>
<kind-code>A1</kind-code>
<document-date>20030102</document-date>
</document-id>
<publication-filing-type>new</publication-filing-type>
<domestic-filing-data>
<application-number>
<doc-number>10141352</doc-number>
</application-number>
<application-number-series-code>10</application-number-series-code>
<filing-date>20020509</filing-date>
</domestic-filing-data>
<foreign-priority-data>
<priority-application-number>
<doc-number>01870100.3</doc-number>
</priority-application-number>
<filing-date>20010510</filing-date>
<country-code>EP</country-code>
</foreign-priority-data>
<technical-information>
<classification-ipc>
<classification-ipc-primary>
<ipc>C07D205/08</ipc>
</classification-ipc-primary>
<classification-ipc-edition>07</classification-ipc-edition>
</classification-ipc>
<classification-us>
<classification-us-primary>
<uspc>
<class>540</class>
<subclass>200000</subclass>
</uspc>
</classification-us-primary>
<classification-us-secondary>
<uspc>
<class>540</class>
<subclass>354000</subclass>
</uspc>
</classification-us-secondary>
<classification-us-secondary>
<uspc>
<class>540</class>
<subclass>361000</subclass>
</uspc>
</classification-us-secondary>
</classification-us>
<title-of-invention>Process for the preparation of azetidones and intermediates thereof</title-of-invention>
</technical-information>
<inventors>
<first-named-inventor>
<name>
<given-name>Marcel</given-name>
<middle-name>Maurice Ghislain</middle-name>
<family-name>Ceresiat</family-name>
</name>
<residence>
<residence-non-us>
<city>Court Saint Etienne</city>
<country-code>BE</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</first-named-inventor>
<inventor>
<name>
<given-name>Marc</given-name>
<family-name>Belmans</family-name>
</name>
<residence>
<residence-non-us>
<city>Tessenderlo</city>
<country-code>BE</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
<inventor>
<name>
<given-name>Jacqueline</given-name>
<family-name>Marchand-Brynaert</family-name>
</name>
<residence>
<residence-non-us>
<city>Marcinelle</city>
<country-code>BE</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
<inventor>
<name>
<given-name>Mathieu</given-name>
<family-name>Laurent</family-name>
</name>
<residence>
<residence-non-us>
<city>Louvain-La-Neuve</city>
<country-code>BE</country-code>
</residence-non-us>
</residence>
<authority-applicant>INV</authority-applicant>
</inventor>
</inventors>
<assignee>
<organization-name>Tessenderio Chemie S.A.</organization-name>
<address>
<address-1>Rue du Trone 130</address-1>
<city>Bruxelles</city>
<postalcode>B-1050</postalcode>
<country>
<country-code>BE</country-code>
</country>
</address>
<assignee-type>03</assignee-type>
</assignee>
<correspondence-address>
<name-1>MILLEN, WHITE, ZELANO &amp; BRANIGAN, P.C.</name-1>
<name-2></name-2>
<address>
<address-1>2200 CLARENDON BLVD.</address-1>
<address-2>SUITE 1400</address-2>
<city>ARLINGTON</city>
<state>VA</state>
<postalcode>22201</postalcode>
<country>
<country-code>US</country-code>
</country>
</address>
</correspondence-address>
</subdoc-bibliographic-information>
<subdoc-abstract>
<paragraph id="A-0001" lvl="0">The present invention relates to a method for the preparation of a compound of the general formula (I) wherein </paragraph>
<paragraph id="A-0002" lvl="1">R<highlight><superscript>1 </superscript></highlight>and R<highlight><superscript>2 </superscript></highlight>each represent independently hydrogen, halogen, hydroxy, thiol, nitro, amino, carboxy, amino derivative, oxy derivative, thio derivative, alkyl, alkenyl, alkynyl, aryl, oxy derivative, amino derivative, thiol derivative, acyl derivative, acyloxy derivative, ester, amido, ether, arylalkyl, heterocycle or Me(OR&prime;)CH wherein R&prime; is hydrogen or R<highlight><superscript>a</superscript></highlight>R<highlight><superscript>b</superscript></highlight>R<highlight><superscript>c</superscript></highlight>Si wherein R<highlight><superscript>a</superscript></highlight>, R<highlight><superscript>b </superscript></highlight>and R<highlight><superscript>c </superscript></highlight>is independently chosen from the group consisting of alkyl, alkenyl, alkynyl, aryl or a heterocycle; </paragraph>
<paragraph id="A-0003" lvl="1">R<highlight><superscript>3 </superscript></highlight>represents a protecting group such as alkyl, alkenyl, alkynyl, or arylalkyl; </paragraph>
<paragraph id="A-0004" lvl="7">wherein this method comprises the reaction of a compound of the general formula (II) in the presence of a halogen-radical source, water and a proton donor suitable as a catalyst. </paragraph>
</subdoc-abstract>
<subdoc-description>
<summary-of-invention>
<section>
<heading lvl="1">FIELD OF THE INVENTION </heading>
<paragraph id="P-0001" lvl="0"><number>&lsqb;0001&rsqb;</number> This invention concerns an improvement in the process for the preparation of azetidones. Azetidones are useful intermediates for preparing carbapenem and penem type antibiotics. </paragraph>
</section>
<section>
<heading lvl="1">BACKGROUND </heading>
<paragraph id="P-0002" lvl="0"><number>&lsqb;0002&rsqb;</number> The present invention relates to an improvement in the process for the preparation of a compound which has the following general formula (I-A) wherein R&prime; is hydrogen or R<highlight><superscript>a</superscript></highlight>R<highlight><superscript>b</superscript></highlight>R<highlight><superscript>c</superscript></highlight>Si wherein R<highlight><superscript>a</superscript></highlight>, R<highlight><superscript>b </superscript></highlight>and R<highlight><superscript>c </superscript></highlight>is independently methyl, ethyl, i-Pr, t-butyl or phenyl; and R&Prime; is hydrogen, alkyl, substituted alkyl, preferably t-butyl, phenyl, substituted phenyl, O-R<highlight><superscript>d </superscript></highlight>or S-R<highlight><superscript>d </superscript></highlight>wherein R<highlight><superscript>d </superscript></highlight>is C<highlight><subscript>1-6 </subscript></highlight>alkyl, substituted alkyl, phenyl or substituted phenyl.  
<chemistry-cwu id="CHEM-US-00001">
<number>1</number>
<image id="EMI-C00001" he="61.9164" wi="157.71105" file="US20030004335A1-20030102-C00001.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00001" file="US20030004335A1-20030102-C00001.CDX"/>
<chemistry-mol-file id="CHEMMOL-00001" file="US20030004335A1-20030102-C00001.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0003" lvl="0"><number>&lsqb;0003&rsqb;</number> Compound of said general formula (I-A) may be prepared by a series of reactions as described hereafter. </paragraph>
<paragraph id="P-0004" lvl="0"><number>&lsqb;0004&rsqb;</number> First, L-threonine is converted to (2R,3R)-cis-2,3-epoxybutanoic acid as described in J. Chrom. A, 832:259-264,1999. The (2R,3R)-cis-2,3-epoxybutanoic acid is next converted to an epoxyamide as described in Tetrahedron 56:3209-3217, 2000. In the following step, said epoxyamide is converted by ring closure to an azetidinone with a nitrogen-protecting group. </paragraph>
<paragraph id="P-0005" lvl="0"><number>&lsqb;0005&rsqb;</number> This nitrogen-protecting group should next be removed. Two methods are currently used to remove said nitrogen-protecting group. (A. H. Berks, Tetrahedron, 52, 331-375 (1996)) </paragraph>
<paragraph id="P-0006" lvl="0"><number>&lsqb;0006&rsqb;</number> A first method uses ceric ammonium nitrate (CAN) as disclosed in Kronenthal et al., J. Org. Chem., 47, 2765 (1982). This method was found to be useful when said nitrogen-protecting group consists of para-methoxyphenyl. (S. Hanessian et al., J.Am.Chem.Soc., 107, 1438-1439 (1985)). </paragraph>
<paragraph id="P-0007" lvl="0"><number>&lsqb;0007&rsqb;</number> The second method also consists of oxydative cleavage. For instance, in case the nitrogen-protecting group is 2,4-dimethoxybenzyl, said nitrogen-protecting group may be removed by the use of potassium persulfate as described in Y. Kita et al., Chem. Pharm. Bull., 40, 1733-1736 (1992). In case the nitrogen-protecting group consists of di(para-methoxyphenyl)methyl, the oxydative cleavage may be done by the use of sodium persulfate as disclosed in Y. Ito et al., Tetrahedron, 45, 5767-5790 (1989), or CAN as disclosed in M. Sunagawa et al., Chem. Pharm. Bull., 39,1931-1938 (1991). </paragraph>
<paragraph id="P-0008" lvl="0"><number>&lsqb;0008&rsqb;</number> However, these deprotection processes as described above are quite difficult and expensive to conduct. This is particularly the case when said nitrogen-protecting group consists of a para-methoxyphenyl (anisyl) group. </paragraph>
<paragraph id="P-0009" lvl="0"><number>&lsqb;0009&rsqb;</number> It is clear that a new process for removing said nitrogen protecting group not having the disadvantages as mentioned above, not requiring a quantitative amount of metal (Ce IV) and still relatively easy to carry out, would be extremely desirable. </paragraph>
</section>
<section>
<heading lvl="1">DESCRIPTION </heading>
<paragraph id="P-0010" lvl="0"><number>&lsqb;0010&rsqb;</number> According to a first aspect, the present invention relates to a method for the preparation of a compound of the general formula (I) wherein </paragraph>
<paragraph id="P-0011" lvl="1"><number>&lsqb;0011&rsqb;</number> R<highlight><superscript>1 </superscript></highlight>and R<highlight><superscript>2 </superscript></highlight>each represent independently hydrogen, halogen, hydroxy, thiol, nitro, amino, carboxy, amino derivative, oxy derivative, thio derivative, alkyl, alkenyl, alkynyl, aryl, oxy derivative, amino derivative, thiol derivative, acyl derivative, acyloxy derivative, ester, amido, ether, arylalkyl, heterocycle or Me(OR&prime;)CH wherein R&prime; is hydrogen or R<highlight><superscript>a</superscript></highlight>R<highlight><superscript>b</superscript></highlight>R<highlight><superscript>c</superscript></highlight>Si wherein R<highlight><superscript>a</superscript></highlight>, R<highlight><superscript>b </superscript></highlight>and R<highlight><superscript>c </superscript></highlight>represent independently alkyl, alkenyl, alkynyl, aryl or a heterocycle, each of said radicals optionally substituted; </paragraph>
<paragraph id="P-0012" lvl="1"><number>&lsqb;0012&rsqb;</number> R<highlight><superscript>3 </superscript></highlight>represents a protecting group such as alkyl, alkenyl, alkynyl or arylalkyl, each optionally substituted; </paragraph>
<paragraph id="P-0013" lvl="7"><number>&lsqb;0013&rsqb;</number> wherein this method comprises the reaction of a compound of the general formula (II) in the presence of a halogen radical source, water and a proton donor as the catalyst, according to the following scheme 1.  
<chemistry-cwu id="CHEM-US-00002">
<number>2</number>
<image id="EMI-C00002" he="77.0553" wi="160.09245" file="US20030004335A1-20030102-C00002.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00002" file="US20030004335A1-20030102-C00002.CDX"/>
<chemistry-mol-file id="CHEMMOL-00002" file="US20030004335A1-20030102-C00002.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0014" lvl="0"><number>&lsqb;0014&rsqb;</number> In the compounds and radicals as described above the term &ldquo;alkyl&rdquo; includes saturated hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof and contains 1-20 carbon atoms, preferably 1-10 carbon atoms and more preferably 1-5 carbon atoms. The alkyl group may optionally be substituted by 1 to 5 substituents independently selected from the group consisting of halogen, hydroxy, oxy derivatives, thiol, thio derivatives, amino, amino derivatives, nitro, acyl derivatives, acyloxy derivatives, carboxy, ester, ether, amido, heterocycle. Preferred alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, iso- or t-butyl. </paragraph>
<paragraph id="P-0015" lvl="0"><number>&lsqb;0015&rsqb;</number> The term &ldquo;alkenyl&rdquo; refers to an univalent C<highlight><subscript>2 </subscript></highlight>to C<highlight><subscript>12 </subscript></highlight>and preferably C<highlight><subscript>2 </subscript></highlight>to C<highlight><subscript>6 </subscript></highlight>straight or branched, hydrocarbon with at least one double bond, optionally substituted with any suitable group, including but not limited to one or more moieties selected from lower alkyl or other groups as described above for the alkyl groups. Non-limiting examples are ethenyl, 1-propenyl, 2-butenyl, 1,3-butadienyl, 2-pentenyl, isopropenyl, styryl, cinnamyl. </paragraph>
<paragraph id="P-0016" lvl="0"><number>&lsqb;0016&rsqb;</number> The term &ldquo;alkynyl&rdquo; refers to an univalent C<highlight><subscript>2 </subscript></highlight>to C<highlight><subscript>12 </subscript></highlight>and preferably C<highlight><subscript>2 </subscript></highlight>to C<highlight><subscript>6 </subscript></highlight>straight or branched hydrocarbon with at least one triple bond, optionally substituted with any suitable group, including but not limited to one or more moieties selected from lower alkyl or other groups as described above for the alkyl groups. Non-limiting examples are ethynyl, propynyl, 2-penten-4-yl, and &mdash;C&equiv;C&mdash;CH<highlight><subscript>2</subscript></highlight>-(alkyl) including &mdash;C&equiv;C&mdash;CH<highlight><subscript>2</subscript></highlight>CH<highlight><subscript>3</subscript></highlight>. </paragraph>
<paragraph id="P-0017" lvl="0"><number>&lsqb;0017&rsqb;</number> The term &ldquo;oxy derivatives&rdquo;, as used above includes &mdash;O&mdash;R<highlight><superscript>4 </superscript></highlight>groups wherein R<highlight><superscript>4 </superscript></highlight>is as defined below. Non-limiting examples are methoxy, ethoxy, phenoxy, benzyloxy, 2-naphtyloxy, 2-pyridyloxy, carbonate. </paragraph>
<paragraph id="P-0018" lvl="1"><number>&lsqb;0018&rsqb;</number> R<highlight><superscript>4 </superscript></highlight>and R<highlight><superscript>5 </superscript></highlight>are the same or not and are independently selected from the group consisting of alkyl, alkenyl, alkynyl, heterocycle, aryl, arylalkyl. R<highlight><superscript>4 </superscript></highlight>and R<highlight><superscript>5 </superscript></highlight>can optionally be substituted with any suitable group, including but not limited to one or more moieties as described above for the alkyl groups. </paragraph>
<paragraph id="P-0019" lvl="0"><number>&lsqb;0019&rsqb;</number> The term &ldquo;thio derivative&rdquo; as used above, includes &mdash;S&mdash;R<highlight><superscript>4 </superscript></highlight>groups wherein R<highlight><superscript>4 </superscript></highlight>is defined above. </paragraph>
<paragraph id="P-0020" lvl="0"><number>&lsqb;0020&rsqb;</number> The term &ldquo;amino derivatives&rdquo; as used above, includes &mdash;NHR<highlight><superscript>4 </superscript></highlight>or &mdash;NR<highlight><superscript>4</superscript></highlight>R<highlight><superscript>5 </superscript></highlight>groups wherein R<highlight><superscript>4 </superscript></highlight>and R<highlight><superscript>5 </superscript></highlight>are defined above. </paragraph>
<paragraph id="P-0021" lvl="0"><number>&lsqb;0021&rsqb;</number> The term &ldquo;aryl&rdquo; as used above, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl, biphenyl, naphthyl, which can optionally be substituted with any suitable group, including but not limited to one or more moieties selected from lower alkyl or other groups as described above for the alkyl groups. The aryl radical consists of 1-3 rings, preferably two rings, and contains 6-30 carbon atoms preferably 6-10 carbon atoms. Non-limiting examples are phenyl, biphenyl, cumenyl, mesityl, tolyl, xylyl, halophenyl, cyanophenyl, nitrophenyl, methoxyphenyl, naphthyl, indenyl, anthryl. </paragraph>
<paragraph id="P-0022" lvl="0"><number>&lsqb;0022&rsqb;</number> The term &ldquo;halogen&rdquo;, as used above, includes an atom of Cl, Br, F, I. </paragraph>
<paragraph id="P-0023" lvl="0"><number>&lsqb;0023&rsqb;</number> The term &ldquo;hydroxy&rdquo;, as used above, represents a group of the formula &mdash;OH. </paragraph>
<paragraph id="P-0024" lvl="0"><number>&lsqb;0024&rsqb;</number> The term &ldquo;thiol&rdquo;, as used above, represents a group of the formula &mdash;SH. </paragraph>
<paragraph id="P-0025" lvl="0"><number>&lsqb;0025&rsqb;</number> The term &ldquo;nitro&rdquo;, as used above, represents a group of the formula &mdash;NO<highlight><subscript>2</subscript></highlight>. </paragraph>
<paragraph id="P-0026" lvl="0"><number>&lsqb;0026&rsqb;</number> The term &ldquo;amino&rdquo;, as used above, represents a group of the formula &mdash;NH<highlight><subscript>2</subscript></highlight>. </paragraph>
<paragraph id="P-0027" lvl="0"><number>&lsqb;0027&rsqb;</number> The term &ldquo;carboxy&rdquo;, as used above, represents a group of the formula &mdash;COOH. </paragraph>
<paragraph id="P-0028" lvl="0"><number>&lsqb;0028&rsqb;</number> The term &ldquo;heterocycle&rdquo;, as used above, refers to an aromatic or non aromatic cyclic alkyl, alkenyl, or alkynyl moiety as defined above, having at least one O, S and/or N atom interrupting the carbocyclic ring structure and optionally, one of the carbon of the carbocyclic ring structure may be replaced by a carbonyl. Non-limiting examples of aromatic heterocycles are pyridyl, furyl, pyrrolyi, thienyl, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, quinazolinyl, quinolizinyl, naphthyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolyl, isobenzofuranyl, benzothienyl, pyrazolyl, indolyl, indolizinyl, purinyl, isoindolyl, carbazolyl, thiazolyl, 1,2,4-thiadiazolyl, thieno(2,3-b)furanyl, furopyranyl, benzofuranyl, benzoxepinyl, isooxazolyl, oxazolyl, thianthrenyl, benzothiazolyl, or benzoxazolyl, cinnolinyl, phthalazinyl, quinoxalinyl, phenanthridinyl, acridinyl, perimidinyl, phenanthrolinyl, phenothiazinyl, furazanyl, isochromanyl, indolinyl, xanthenyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolopyrimidinyl optionally substituted as described above for the alkyl groups. Non-limiting examples of non aromatic heterocycles are tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperidyl, piperazinyl, imidazolidinyl, morpholino, morpholinyl, 1-oxaspiro(4.5)dec-2-yl, pyrrolidinyl, 2-oxo-pyrrolidinyl, sugar moieties (i.e. glucose, pentose, hexose, ribose, fructose, which may also be substituted) or the same which can optionally be substituted with any suitable group, including but not limited to one or more moieties selected from lower alkyl, or other groups as described above for the alkyl groups. The term &ldquo;heterocycle&rdquo; also includes bicyclic, tricyclic and tetracyclic, spiro groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring or another monocyclic heterocyclic ring or where a monocyclic heterocyclic group is bridged by an alkyl group, such as quinuclidinyl, 7-azabicyclo(2.2.1)heptanyl, 7-oxabicyclo(2.2.1)heptanyl, 8-azabicyclo(3.2.1)octanyl. </paragraph>
<paragraph id="P-0029" lvl="0"><number>&lsqb;0029&rsqb;</number> The term &ldquo;arylalkyl&rdquo;, as used above, represents a group of the formula -L<highlight><superscript>1</superscript></highlight>-aryl in which L<highlight><superscript>1 </superscript></highlight>is as defined below and &ldquo;aryl&rdquo; as defined above. Non-limiting examples are benzyl, halobenzyl, cyanobenzyl, methoxybenzyl, (4,6-dimethoxybenzyl), nitrobenzyl, 2-phenylethyl, diphenylmethyl, di(4-ethoxyphenyl)methyl, di(4-methoxyphenyl)methyl, (4-methoxyphenyl)phenylmethyl, indenyl, anthracenylmethyl. </paragraph>
<paragraph id="P-0030" lvl="0"><number>&lsqb;0030&rsqb;</number> L<highlight><superscript>1 </superscript></highlight>is selected from the group of C<highlight><subscript>1 </subscript></highlight>to C<highlight><subscript>12 </subscript></highlight>preferably C<highlight><subscript>1</subscript></highlight>-C<highlight><subscript>5 </subscript></highlight>straight or branched alkyl, alkylene or alkynylene groups. </paragraph>
<paragraph id="P-0031" lvl="0"><number>&lsqb;0031&rsqb;</number> The term &ldquo;acyl derivative&rdquo; as used above, represents a radical derived from carboxylic acid and thus includes groups of the formula R<highlight><superscript>4</superscript></highlight>&mdash;CO&mdash;, wherein R<highlight><superscript>4 </superscript></highlight>is defined above and may also be hydrogen. Non-limiting examples are formyl, acetyl, propionyl, isobutyryl, pivaloyl, valeryl, lauroyl, heptanedioyl, cyclohexanecarbonyl, crotonoyl, fumaroyl, acryloyl, benzoyl, naphthoyl, furoyl, nicotinoyl, 4-carboxybutanoyl, oxalyl, ethoxalyl, cysteinyl, oxamoyl. </paragraph>
<paragraph id="P-0032" lvl="0"><number>&lsqb;0032&rsqb;</number> The term &ldquo;acyloxy derivatives&rdquo; as used above, represents a radical of carboxylic acid and thus includes groups of the formula R<highlight><superscript>4</superscript></highlight>&mdash;CO&mdash;O&mdash;, wherein R<highlight><superscript>4 </superscript></highlight>is defined above and may also be hydrogen. </paragraph>
<paragraph id="P-0033" lvl="0"><number>&lsqb;0033&rsqb;</number> The term &ldquo;ester&rdquo; means a group of formula &mdash;COO&mdash;R<highlight><superscript>4 </superscript></highlight>wherein R<highlight><superscript>4 </superscript></highlight>is defined above. </paragraph>
<paragraph id="P-0034" lvl="0"><number>&lsqb;0034&rsqb;</number> The term &ldquo;ether&rdquo; means a group selected from C<highlight><subscript>1 </subscript></highlight>to C<highlight><subscript>50 </subscript></highlight>preferably C<highlight><subscript>1 </subscript></highlight>to C<highlight><subscript>12 </subscript></highlight>straight or branched alkyl, or C<highlight><subscript>2 </subscript></highlight>to C<highlight><subscript>50 </subscript></highlight>preferably C<highlight><subscript>2 </subscript></highlight>to C<highlight><subscript>12 </subscript></highlight>straight or branched alkenyl or alkynyl groups or a combination of the same, interrupted by one or more oxygen atoms. </paragraph>
<paragraph id="P-0035" lvl="0"><number>&lsqb;0035&rsqb;</number> The term &ldquo;amido&rdquo; means a group of formula &mdash;CONH<highlight><subscript>2 </subscript></highlight>or &mdash;CONHR<highlight><superscript>4 </superscript></highlight>or &mdash;CONR<highlight><superscript>4</superscript></highlight>R<highlight><superscript>5 </superscript></highlight>wherein R<highlight><superscript>4 </superscript></highlight>and R<highlight><superscript>5 </superscript></highlight>are defined above. </paragraph>
<paragraph id="P-0036" lvl="0"><number>&lsqb;0036&rsqb;</number> The term &ldquo;alkylene&rdquo; refers to an alkyl moiety as described above in which a hydrogen atom has been removed to yield a divalent radical. Non-limiting example is &mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;CH(CH<highlight><subscript>3</subscript></highlight>)&mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;. </paragraph>
<paragraph id="P-0037" lvl="0"><number>&lsqb;0037&rsqb;</number> The term &ldquo;alkenylene&rdquo; refers to an alkenyl moiety as described above in which a hydrogen atom has been removed to yield a divalent radical. Non-limiting example is &mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;CH&equiv;CH&mdash;CH<highlight><subscript>2</subscript></highlight>&mdash;. </paragraph>
<paragraph id="P-0038" lvl="0"><number>&lsqb;0038&rsqb;</number> The term &ldquo;alkynylene&rdquo; refers to an alkynyl moiety as described above in which a hydrogen atom has been removed to yield a divalent radical. Non-limiting example is &mdash;C&equiv;C&mdash;C(CH<highlight><subscript>3</subscript></highlight>)<highlight><subscript>2</subscript></highlight>&mdash;. </paragraph>
<paragraph id="P-0039" lvl="0"><number>&lsqb;0039&rsqb;</number> According to yet a more preferred embodiment, the present invention relates to the method of the invention as described above wherein in said compound of the general formula (I) R<highlight><superscript>1 </superscript></highlight>represents Me(OR&prime;)CH wherein R&prime; is hydrogen. </paragraph>
<paragraph id="P-0040" lvl="0"><number>&lsqb;0040&rsqb;</number> According to yet another more preferred embodiment, the present invention relates to the method of the invention as described above wherein in said compound of the general formula (I) R<highlight><superscript>1 </superscript></highlight>represents Me(OR&prime;)CH wherein R&prime; is R<highlight><superscript>a</superscript></highlight>R<highlight><superscript>b</superscript></highlight>R<highlight><superscript>c</superscript></highlight>Si wherein R<highlight><superscript>a</superscript></highlight>, R<highlight><superscript>b </superscript></highlight>and R<highlight><superscript>c </superscript></highlight>is methyl, ethyl, i-Pr, t-butyl or phenyl. </paragraph>
<paragraph id="P-0041" lvl="0"><number>&lsqb;0041&rsqb;</number> According to yet another more preferred embodiment, the present invention relates to the method of the invention as described above wherein in said compound of the general formula (I) R<highlight><superscript>2 </superscript></highlight>represents an acyl derivative of the formula R&Prime;&mdash;CO&mdash; wherein R&Prime; is hydrogen, alkyl, substituted alkyl, preferably t-butyl, phenyl, substituted phenyl, OR<highlight><superscript>d</superscript></highlight>, SR<highlight><superscript>d </superscript></highlight>wherein R<highlight><superscript>d </superscript></highlight>is C<highlight><subscript>16 </subscript></highlight>alkyl, phenyl, substituted phenyl. </paragraph>
<paragraph id="P-0042" lvl="0"><number>&lsqb;0042&rsqb;</number> According to yet another more preferred embodiment, the present invention relates to the method of the invention as described above wherein in said compound of the general formula (I) R<highlight><superscript>3 </superscript></highlight>represents an arylalkyl, preferably methyl-bisphenyl or substituted methyl-bisphenyl. These substituents are preferred because the hydrogen of the methyl group in methyl-bisaryl groups can be easily abstract with a radical reagent. The resulting stabilized bis-aryl-methylene radical can be further quenched with a halogen radical. </paragraph>
<paragraph id="P-0043" lvl="0"><number>&lsqb;0043&rsqb;</number> According to yet another embodiment, said halogen radical source is provided from a N-halogeno-compounds which hemolytic cleavage furnishes a nitrogen radical and a halogen radical. The nitrogen radical abstracts the proton from the bis-phenyl-methyl group and the halogen radical traps the so-formed bis-phenyl-methylene radical. The cleavage of the N-halogeno reagent can be obtained by thermal activation, light activation, or activation with radical initiators such as AIBN (azo-bis-isobutyronitrile) and related azo compounds. Suitable N-halogeno reagents for use in the method of the invention are N-halogeno-amines, N-halogeno-amides, N-halogen-imides, N-halogeno-ureas, N-halogeno-carbamates, or N-halogeno-hydantoines. </paragraph>
<paragraph id="P-0044" lvl="0"><number>&lsqb;0044&rsqb;</number> According to a more preferred embodiment, said halogen radical source for use in the method of the invention as described above is N-bromosuccinimide (NBS) or N-bromophtalimide which are commercially available. </paragraph>
<paragraph id="P-0045" lvl="0"><number>&lsqb;0045&rsqb;</number> According to yet another aspect, the present invention relates to a method for the preparation of a compound of the general formula (I-A) wherein R&prime; and R&Prime; are as noted above, Y and Y&prime; are alkyl, alkyloxy, halogen or preferably hydrogen, wherein this method comprises the reaction of a compound of the general formula (II-B) in the presence of a halogen-containing nitrogen source, preferably N-bromosuccinimide (NBS), activated by light (hv) and in the presence of water and a proton donor as the catalyst, according to the following scheme 2.  
<chemistry-cwu id="CHEM-US-00003">
<number>3</number>
<image id="EMI-C00003" he="227.3103" wi="215.8002" file="US20030004335A1-20030102-C00003.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00003" file="US20030004335A1-20030102-C00003.CDX"/>
<chemistry-mol-file id="CHEMMOL-00003" file="US20030004335A1-20030102-C00003.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0046" lvl="0"><number>&lsqb;0046&rsqb;</number> This method as described above converting compound of general formula (II-B) to (I-A) can be divided into three steps, as illustrated in the scheme 3 below. In the first step, the compound of general formula (II-B) is halogenated by means of a halogen radical generated by the halogen-containing nitrogen source in the presence of light, forming a general compound of formula (II-C). In the presence of water said compound of general formula (II-C) is next converted into a compound of general formula (II-D). In the presence of a proton donor as the catalyst (an acid according to Br&ouml;nsted), said compound of general formula (II-D) is converted into the compound of general formula (I-A) with expulsion of bis-aryl-ketone. Another advantage of the process according to the invention is that it can be performed in &ldquo;one-pot&rdquo; without isolation of intermediates, or with the isolation of intermediates II-D.  
<chemistry-cwu id="CHEM-US-00004">
<number>4</number>
<image id="EMI-C00004" he="517.2741" wi="215.8002" file="US20030004335A1-20030102-C00004.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00004" file="US20030004335A1-20030102-C00004.CDX"/>
<chemistry-mol-file id="CHEMMOL-00004" file="US20030004335A1-20030102-C00004.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0047" lvl="0"><number>&lsqb;0047&rsqb;</number> This present method of this invention, in particular removing the nitrogen-protecting group in the presence of a halogen-containing nitrogen source and light, and in the presence of water and a proton donor, have several advantages compared to the method currently known in the art. In particular, the method of this invention results in a higher production yield of azetidinones and makes use of environmentally acceptable conditions avoiding the utilization of large quantities of a metal such as Cerium IV. </paragraph>
<paragraph id="P-0048" lvl="0"><number>&lsqb;0048&rsqb;</number> Moreover, this method of N-deprotection can be generalized in all fields of organic synthesis, and more particularly in peptide synthesis where new orthogonal methods are useful. </paragraph>
<paragraph id="P-0049" lvl="0"><number>&lsqb;0049&rsqb;</number> According to yet another aspect, the present invention relates to a method for the preparation of a compound of the general formula (I-A) wherein R&prime;, R&Prime;, Y and Y&prime; are as noted above, wherein this method comprises the steps of </paragraph>
<paragraph id="P-0050" lvl="1"><number>&lsqb;0050&rsqb;</number> (a) converting L-threonine to sodium (2S,3R)-cis-2,3-epoxybutanoate, </paragraph>
<paragraph id="P-0051" lvl="1"><number>&lsqb;0051&rsqb;</number> (b) converting said sodium (2S,3R)-cis-2,3-epoxybutanoate to an epoxyamide of general formula (A) </paragraph>
<paragraph id="P-0052" lvl="1"><number>&lsqb;0052&rsqb;</number> (c) cyclization of said compound of general formula (A) into N-protected azetidinone (II-B), and </paragraph>
<paragraph id="P-0053" lvl="1"><number>&lsqb;0053&rsqb;</number> (d) removing the N-protecting group of the compound of the general formula (II-B) in the presence of a halogen-containing nitrogen source, preferably N-bromosuccinimide and light, and in the presence of water and a proton donor as the catalyst, according to the following scheme 4.  
<chemistry-cwu id="CHEM-US-00005">
<number>5</number>
<image id="EMI-C00005" he="424.8531" wi="215.8002" file="US20030004335A1-20030102-C00005.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00005" file="US20030004335A1-20030102-C00005.CDX"/>
<chemistry-mol-file id="CHEMMOL-00005" file="US20030004335A1-20030102-C00005.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0054" lvl="0"><number>&lsqb;0054&rsqb;</number> According to a more preferred embodiment, in the method of the invention as described above an extra step may optionally be present which comprises a silanating step for the protection of the hydroxyl function (R&prime;&boxH;H), performed either before or after the deprotecting step (d). </paragraph>
<paragraph id="P-0055" lvl="0"><number>&lsqb;0055&rsqb;</number> The full process for the preparation of azetidinones starting from (2R,3R)-cis-2,3-epoxybutanoate according to the new process of this invention is illustrated in the following scheme 5 and described hereafter. </paragraph>
<paragraph id="P-0056" lvl="0"><number>&lsqb;0056&rsqb;</number> Sodium (2R,3R)-cis-2,3-epoxybutanoate is prepared from L-threonine according to known procedures as described in Petit Y. et al., Synthesis 1988, 538 and Demillequand M. et al., J Chromatogr., A. 1999, 832, 259. Converting said (2R,3R)-cis-2,3-epoxybutanoate to an epoxyamide of the general formula (A) can be done by coupling to N-(bis-aryl-methyl)-N-(acyl-methyl) amine in several conditions of carboxyl activation such as SOCl<highlight><subscript>2</subscript></highlight>/THF; SOCl<highlight><subscript>2</subscript></highlight>&plus;pyridine/benzene; (COCl)<highlight><subscript>2</subscript></highlight>&plus;pyridine/THF; 2,3,5-trichlorobenzoyl chloride/DMF; i-butyl chloroformate/DMF or CH<highlight><subscript>3</subscript></highlight>CN; pivaloyl chloride&plus;pyridine/CH<highlight><subscript>3</subscript></highlight>CN. The next step consists of cyclization in the presence of a base such as K<highlight><subscript>2</subscript></highlight>CO<highlight><subscript>3 </subscript></highlight>in DMF (dimethylformamide) or LiHMDS (lithium hexamethyldisilazide) in benzene or THF (tetrahydrofuran) as described in Deng B. -L. et al. Tetrahedron, 2000, 56, 3209-3217. The N-protecting group is next removed according to the method of this invention as described above. The compound of the general formula (II-B) is reacted with N-halogenosuccinimide, for instance N-bromosuccinimide, in the presence of light. This reaction results in a compound of the general formula (II-C). In the presence of water, said compound of the general formula (II-C) is converted in the compound of the general formula (II-D), which is next converted into a compound of the general formula (I-A) by reaction with a proton donor as the catalyst. Said compound of the general formula (I-A) may next be silanated as illustrated in the last step of scheme 5. Optionally, silanation can be done before the deprotecting step.  
<chemistry-cwu id="CHEM-US-00006">
<number>6</number>
<image id="EMI-C00006" he="700.4151" wi="215.8002" file="US20030004335A1-20030102-C00006.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00006" file="US20030004335A1-20030102-C00006.CDX"/>
<chemistry-mol-file id="CHEMMOL-00006" file="US20030004335A1-20030102-C00006.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0057" lvl="0"><number>&lsqb;0057&rsqb;</number> According to yet another embodiment, said proton donor in the method of the invention as described above is selected from the groups consisting of carboxylic acids (such as trichloroacetic acid, trifluoroacetic acid, formic acid, . . . ), sulfonic acids (such as methane sulfonic acid, trifluoromethane sulfonic acid, para-toluene sulfonic acid, . . . ) and inorganic acids (such as hydrochloric acid, sulfuric acid, perchloric acid, phosphoric acid, . . . ). </paragraph>
<paragraph id="P-0058" lvl="0"><number>&lsqb;0058&rsqb;</number> According to yet another aspect, the present invention relates to compounds as a final product or as an intermediate obtainable by any of the methods of the invention as described above. </paragraph>
<paragraph id="P-0059" lvl="0"><number>&lsqb;0059&rsqb;</number> According to yet another aspect, the present invention also relates to a compound obtained by any of the methods of the invention as described above. </paragraph>
<paragraph id="P-0060" lvl="0"><number>&lsqb;0060&rsqb;</number> According to yet another aspect, the present invention also relates to a compound of the general formula (I-A) as noted above wherein R&prime; is R<highlight><superscript>a</superscript></highlight>R<highlight><superscript>b</superscript></highlight>R<highlight><superscript>c</superscript></highlight>Si wherein R<highlight><superscript>a</superscript></highlight>, R<highlight><superscript>b </superscript></highlight>and R<highlight><superscript>c </superscript></highlight>are as noted above. </paragraph>
<paragraph id="P-0061" lvl="0"><number>&lsqb;0061&rsqb;</number> Furthermore, the invention also relates to pharmaceutically acceptable salts, geometrical isomers (including cis and trans, Z and E isomers), enantiomers, diastereoisomers and mixtures (including racemates) of the compounds of the invention as defined above. </paragraph>
<paragraph id="P-0062" lvl="0"><number>&lsqb;0062&rsqb;</number> The &ldquo;pharmaceutically acceptable salts&rdquo; according to the invention are meant to comprise the therapeutically active non-toxic base and acid salt forms which the compounds of the invention are able to form. </paragraph>
<paragraph id="P-0063" lvl="0"><number>&lsqb;0063&rsqb;</number> The acid salt form of a compound of the invention that occurs in its free form as a base can be obtained by treating said free base form with an appropriate acid such as an inorganic acid, for example, hydrogen halides e.g. hydrochloric or hydrobromic, sulfuric, nitric, phosphoric and the like acids; or an organic acid, such as, for example, acetic, hydroxyacetic, propanoic, lactic, pyruvic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like. </paragraph>
<paragraph id="P-0064" lvl="0"><number>&lsqb;0064&rsqb;</number> The compounds of the invention containing acidic protons may be converted into their therapeutically active non-toxic base, i.e. metal or amine, addition salt forms by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like. </paragraph>
<paragraph id="P-0065" lvl="0"><number>&lsqb;0065&rsqb;</number> Conversely said salt forms can be converted into the free forms by treatment with an appropriate base or acid. </paragraph>
<paragraph id="P-0066" lvl="0"><number>&lsqb;0066&rsqb;</number> This invention also relates to all stereoisomeric forms such as optical enantiomeric and diastereoisomeric forms of the compounds of formula I or mixtures (including racemates) thereof. The compounds of the invention and some of their intermediates have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondance with the rules described in Pure Appl. Chem., 45 (1976) 11-30. </paragraph>
<paragraph id="P-0067" lvl="0"><number>&lsqb;0067&rsqb;</number> Furthermore certain compounds of the invention which contain alkenyl groups may exist as Z or E isomers. In each instance, the invention includes both mixtures and separate individual isomers. </paragraph>
<paragraph id="P-0068" lvl="0"><number>&lsqb;0068&rsqb;</number> Some of the compounds of the invention may also exist in their tautomeric forms. Such forms although not explicity indicated in the above formula are intended to be included within the scope of the present invention. </paragraph>
<paragraph id="P-0069" lvl="0"><number>&lsqb;0069&rsqb;</number> The compound of the invention and its salt can be in the form of a solvate, which is included within the scope of the present invention. The solvate are for example hydrates, alcoholates and the like. </paragraph>
<paragraph id="P-0070" lvl="0"><number>&lsqb;0070&rsqb;</number> In the preparation methods according to the invention, the reaction products may be isolated from the reaction medium and, if necessary, further purified according to methodologies generally known in the art such as, for example extraction, crystallization, distillation, trituration and chromatography, or any combination of the same. </paragraph>
<paragraph id="P-0071" lvl="0"><number>&lsqb;0071&rsqb;</number> Pure stereochemically isomeric forms of said compounds of the invention (and said intermediates) can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like methods. </paragraph>
<paragraph id="P-0072" lvl="0"><number>&lsqb;0072&rsqb;</number> Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, to mixtures of diastereoisomeric salts or compounds; then physically separating said mixtures of diastereoisomeric salts or compounds by, for example, selective crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers. </paragraph>
<paragraph id="P-0073" lvl="0"><number>&lsqb;0073&rsqb;</number> Alternatively, pure stereochemically isomeric forms may be obtained by using enantioselective reactions according to procedures known by the person skilled in the art. </paragraph>
<paragraph id="P-0074" lvl="0"><number>&lsqb;0074&rsqb;</number> Another alternative manner of separating the enantiomeric forms of the compounds of the invention and intermediates involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase. Some of the intermediates are known compounds or may be prepared according to art-known procedures. </paragraph>
<paragraph id="P-0075" lvl="0"><number>&lsqb;0075&rsqb;</number> The following examples are provided for illustrative purposes only and are not intended, nor should they be construed, as limiting the invention in any manner. Those skilled in the art will appreciate that routine variations and modifications of the following examples can be made without exceeding the spirit or scope of the invention. </paragraph>
<paragraph id="P-0076" lvl="0"><number>&lsqb;0076&rsqb;</number> Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. </paragraph>
<paragraph id="P-0077" lvl="0"><number>&lsqb;0077&rsqb;</number> In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated. </paragraph>
</section>
</summary-of-invention>
<detailed-description>
<section>
<heading lvl="1">EXAMPLES </heading>
</section>
<section>
<heading lvl="1">Example 1 </heading>
</section>
<section>
<heading lvl="1">Conversion of N-(benzhydryl)-N-(pivaloylmethyl) (2R, 3R)-cis-2,3-epoxybutyramide to (3S, 4S)-1-benzhydryl-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone </heading>
<paragraph id="P-0078" lvl="0"><number>&lsqb;0078&rsqb;</number>  
<chemistry-cwu id="CHEM-US-00007">
<number>7</number>
<image id="EMI-C00007" he="151.4457" wi="216.027" file="US20030004335A1-20030102-C00007.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00007" file="US20030004335A1-20030102-C00007.CDX"/>
<chemistry-mol-file id="CHEMMOL-00007" file="US20030004335A1-20030102-C00007.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0079" lvl="7"><number>&lsqb;0079&rsqb;</number> To a solution of N-(benzhydryl)-N-(pivaloylmethyl) (2R, 3R)-cis-2,3-epoxybutyramide 1s (3.7 g, 10.13 mmol) in THF (70 mL), cooled at &minus;5&deg; C., was added dropwise a solution of lithium hexamethyidisilazide (20 mL 1 M LiHMDS) in THF (90 mL). The mixture was kept at &minus;5&deg; C. during the addition, then stirred at 0&deg; C. for 2 h. After addition of 1N HCl (75 mL), the mixture was extracted with ethyl acetate (2&times;50 mL). The organic phase was washed successively with 5% NaHCO<highlight><subscript>3 </subscript></highlight>(2&times;75 mL) and brine (2&times;75 mL), dried over MgSO<highlight><subscript>4 </subscript></highlight>and concentrated under vacuum. Flash chromatography on silica gel (CH<highlight><subscript>2</subscript></highlight>Cl<highlight><subscript>2</subscript></highlight>&mdash; EtOAc, 10:1; R<highlight><subscript>F</subscript></highlight>&equals;0.15) gave (3S, 4S)-1-benzhydryl-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone (3.33 g, 90% yield) as a pale yellow oil which crystallized from ethanol, or ethyl acetate&mdash;hexane (1: 4): mp 168-170&deg; C.; IR (KBr) &ngr;&equals;3500, 1759, 1704, 1457, 1367 cm<highlight><superscript>&minus;1</superscript></highlight>; <highlight><superscript>1</superscript></highlight>H NMR (500 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;&equals;0.90 (s, 9H), 1.38 (d, 3H, J&equals;6.4 Hz), 2.04 (br s, 1H), 2.89 (dd, 1H, J&equals;2.1 and 6.4 Hz), 4.21 (dq, 1H, J&equals;6.4 and 6.4 Hz), 4.52 (d, 1H, J&equals;2.1 Hz), 5.69 (s, 1H), 7.20-7.40 (m, 10H); HRMS: 365.1988 (calcd for C<highlight><subscript>23</subscript></highlight>H<highlight><subscript>27</subscript></highlight>NO<highlight><subscript>3</subscript></highlight>: 365.1991). </paragraph>
</section>
<section>
<heading lvl="1">Example 2 </heading>
</section>
<section>
<heading lvl="1">Conversion of N-(Benzhydryl)-N-(phenacyl) (2R, 3R)-cis-2,3-epoxybutyramide to (3S, 4S)-1-benzhydryl-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-benzoyl-2-azetidinone </heading>
<paragraph id="P-0080" lvl="0"><number>&lsqb;0080&rsqb;</number>  
<chemistry-cwu id="CHEM-US-00008">
<number>8</number>
<image id="EMI-C00008" he="151.4457" wi="216.027" file="US20030004335A1-20030102-C00008.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00008" file="US20030004335A1-20030102-C00008.CDX"/>
<chemistry-mol-file id="CHEMMOL-00008" file="US20030004335A1-20030102-C00008.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0081" lvl="7"><number>&lsqb;0081&rsqb;</number> N-(Benzhydryl)-N-(phenacyl) (2R, 3R)-cis-2,3-epoxybutyramide (1.04 g, 2.7 mmol) was reacted with LiHMDS as described in example 1, to furnish (3S, 4S)-1-benzhydryl-3&mdash;&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-benzoyl-2-azetidinone (0.593 g, 57% yield) as a white gum: IR (KBr) &dgr;&equals;3400, 1741, 1685, 1450 cm <highlight><superscript>1</superscript></highlight>; <highlight><superscript>1</superscript></highlight>H NMR (500 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &ngr;&equals;1.20 (d, 3H, J&equals;6.3 Hz), 2.10 (br, s, 1H), 3.11 (dd, 1H, J&equals;2.3 and 5.2 Hz), 4.31 (dq, 1H, J&equals;5.2 and 6.3 Hz), 5.07 (d, 1H, J&equals;2.3 Hz), 5.59 (s, 1H), 7.15-7.40 (m, 12H), 7.50 (t, 1H, J&equals;7.7 Hz), 7.70 (d, 2H, J&equals;7.7 Hz); HRMS: 385.1692 (calcd for C<highlight><subscript>25</subscript></highlight>H<highlight><subscript>23</subscript></highlight>NO<highlight><subscript>3</subscript></highlight>: 385.1678). </paragraph>
</section>
<section>
<heading lvl="1">Example 3 </heading>
</section>
<section>
<heading lvl="1">Conversion of N-(4,4&prime;-Dimethoxybenzhydryl)-N-(pivaloylmethyl) (2R, 3R)-cis-2,3-epoxybutyramide to (3S, 4S)-1-(4,4&prime;-dimethoxybenzhydryl)-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone </heading>
<paragraph id="P-0082" lvl="0"><number>&lsqb;0082&rsqb;</number>  
<chemistry-cwu id="CHEM-US-00009">
<number>9</number>
<image id="EMI-C00009" he="283.24485" wi="216.027" file="US20030004335A1-20030102-C00009.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00009" file="US20030004335A1-20030102-C00009.CDX"/>
<chemistry-mol-file id="CHEMMOL-00009" file="US20030004335A1-20030102-C00009.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0083" lvl="7"><number>&lsqb;0083&rsqb;</number> N-(4,4&prime;-Dimethoxybenzhydryl)-N-(pivaloylmethyl) (2R, 3R)-cis-2,3-epoxybutyramide (0.34 g, 0.80 mmol) was reacted with LiHMDS as described in example 1, to furnish (3S, 4S)-1-(4,4&prime;-dimethoxybenzhydryl)-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone (0.21 g, 60% yield) as a white solid: IR (KBr): 2985, 1786, 1683, 1612 cm<highlight><superscript>&minus;1</superscript></highlight>; <highlight><superscript>1</superscript></highlight>H NMR (200 MHz, CDCl<highlight><subscript>3</subscript></highlight>): 0.93 (s, 9H), 1.36 (d, 3H, J&equals;6.3 Hz), 2.03 (br s, 1H), 2.87 (dd, 1H, J&equals;2.1 and 5.9 Hz), 3.76 and 3.78 (s, 6H), 4.21 (dq, 1H, J&equals;5.9 and 6.3 Hz), 4.50 (d, 1H, J &equals;2.1 Hz), 5.57 (s, 1H), 6.80-6.88 (m, 4H), 7.16-7.27 (m, 4H). Anal. calcd for C<highlight><subscript>25</subscript></highlight>H<highlight><subscript>31</subscript></highlight>O<highlight><subscript>5</subscript></highlight>N: C, 70.57; H, 7.34; N, 3.29&mdash;Found: C, 70.12; H, 7.15; N, 3.58. </paragraph>
</section>
<section>
<heading lvl="1">Example 4 </heading>
</section>
<section>
<heading lvl="1">Conversion of (3S,4S)-1-benzhydryl-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone to (3S, 4S)-1-benzhydryl-3-&lsqb;(5R)-1&prime;-t-butyldimethylsilyloxyethyl&rsqb;-4-pivaloyl-2-azetidinone </heading>
<paragraph id="P-0084" lvl="0"><number>&lsqb;0084&rsqb;</number>  
<chemistry-cwu id="CHEM-US-00010">
<number>10</number>
<image id="EMI-C00010" he="183.141" wi="216.027" file="US20030004335A1-20030102-C00010.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00010" file="US20030004335A1-20030102-C00010.CDX"/>
<chemistry-mol-file id="CHEMMOL-00010" file="US20030004335A1-20030102-C00010.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0085" lvl="7"><number>&lsqb;0085&rsqb;</number> t-Butyldimethylsilyl chloride (2.65 g, 18 mmol) and imidazole (2.15 g, 32 mmol) were added to a solution of (3S, 4S)-1-benzhydryl-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone (1.03 g, 2.82 mmol) in DMF (50 mL). The mixture was stirred, under argon atmosphere, at room temperature, during 48 h, then diluted with ethyl acetate (50 mL). The organic phase was washed successively with water (2&times;50 mL) and brine (2&times;50 mL). Drying over MgSO<highlight><subscript>4</subscript></highlight>, concentration and flash chromatography on silica gel (elution with CH<highlight><subscript>2</subscript></highlight>Cl<highlight><subscript>2</subscript></highlight>; R<highlight><subscript>f</subscript></highlight>&equals;0.08) gave (3S, 4S)-1-benzhydryl-3-&lsqb;(5R)-1&prime;-t-butyldimethylsilyloxyethyl&rsqb;-4-pivaloyl-2-azetidinone as a colourless oil (1.34 g, 93% yield): IR (film) &ngr;&equals;1768, 1710 cm<highlight><superscript>&tilde;l</superscript></highlight>; <highlight><superscript>1</superscript></highlight>H NMR (CDCl<highlight><subscript>3, 200 </subscript></highlight>MHz) &dgr;&equals;0.13 (s, 6H), 0.87 (s, 9H), 0.93 (s, 9H), 1.30 (d 3H, J&equals;6.3 Hz), 2.82 (dd, 1H, J&equals;1.9 and 5.5 Hz), 4.27 (dq, 1H, J&equals;5.5 and 6.3 Hz), 4.58 (d, 1H, J&equals;1.9 Hz), 5.68 (s, 1H), 7.2-7.4 (m, 1 OH); Anal. calcd for C<highlight><subscript>29</subscript></highlight>H<highlight><subscript>41</subscript></highlight>O<highlight><subscript>3</subscript></highlight>NSi: C, 72.61; H, 8.61; N, 2.92&mdash;Found: C, 72.58; H, 8.71; N, 2.88. </paragraph>
</section>
<section>
<heading lvl="1">Example 5 </heading>
</section>
<section>
<heading lvl="1">Conversion of (3S, 4S)-1-benzhydryl-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone to (3S, 4S)-1-(diphenyl)hydroxymethyl-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone </heading>
<paragraph id="P-0086" lvl="0"><number>&lsqb;0086&rsqb;</number>  
<chemistry-cwu id="CHEM-US-00011">
<number>11</number>
<image id="EMI-C00011" he="193.2336" wi="216.027" file="US20030004335A1-20030102-C00011.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00011" file="US20030004335A1-20030102-C00011.CDX"/>
<chemistry-mol-file id="CHEMMOL-00011" file="US20030004335A1-20030102-C00011.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0087" lvl="7"><number>&lsqb;0087&rsqb;</number> A solution of (3S, 4S)-1-benzhydryl-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone (0.52 g, 1.4 mmol) and N-bromosuccinimide (NBS) (0.32 g, 1.8 mmol) in chlorobenzene (50 mL) and water (5 mL) was stirred at room temperature, overnight, under the irradiation of the fume hood&apos;s lamp. After dilution with CH<highlight><subscript>2</subscript></highlight>Cl<highlight><subscript>2 </subscript></highlight>(50 mL), the organic phase was washed with 5% aqueous NaHSO<highlight><subscript>3 </subscript></highlight>(100 mL), then concentrated under vacuum at 20&deg; C. to give crude (3S, 4S)-1-(diphenyl)hydroxymethyl-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone as a pale yellow solid (0.53 g, 100% yield): <highlight><superscript>1</superscript></highlight>H NMR (200 MHz, CDCl<highlight><subscript>3</subscript></highlight>) &dgr;&equals;0.84 (s, 9H), 1.43 (d, 3H, J&equals;6.6 Hz), 2.50 (br s, 1H), 2.87 (dd, 1H, J&equals;2.1 and 6.3 Hz), 4.26 (dq, 1H, J&equals;6.3 and 6.3 Hz), 4.69 (d, 1H, J&equals;2.1 Hz), 5.12 (brs, 1H), 7.2-7.8 (m, 10H). </paragraph>
</section>
<section>
<heading lvl="1">Example 6 </heading>
</section>
<section>
<heading lvl="1">Conversion of (3S, 4S)-1-(diphenyl)hydroxymethyl-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone to (3S, 4S)-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone </heading>
<paragraph id="P-0088" lvl="0"><number>&lsqb;0088&rsqb;</number>  
<chemistry-cwu id="CHEM-US-00012">
<number>12</number>
<image id="EMI-C00012" he="177.38595" wi="216.027" file="US20030004335A1-20030102-C00012.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00012" file="US20030004335A1-20030102-C00012.CDX"/>
<chemistry-mol-file id="CHEMMOL-00012" file="US20030004335A1-20030102-C00012.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0089" lvl="7"><number>&lsqb;0089&rsqb;</number> A solution of (3S, 4S)-1-(diphenyl)hydroxymethyl-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone (0.53 g, 1.4 mmol) and p-toluenesulfonic acid (30 mg, 0.16 mmol) in, acetonitrile-water (1:1, v/v; 20 mL) was stirred overnight at room temperature. After dilution with ethyl acetate (20 mL), the organic phase was washed with 5% aqueous NaHCO<highlight><subscript>3 </subscript></highlight>(30 mL), then concentrated under vacuum and purified by flash chromatography on silica gel (elution with CH<highlight><subscript>2</subscript></highlight>Cl<highlight><subscript>2</subscript></highlight>: EtOAc, 10:1, then with EtOAc; R<highlight><subscript>f</subscript></highlight>&equals;0.52) to give (3S, 4S)-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone as a white solid (0.265 g, 95% yield): <highlight><superscript>1</superscript></highlight>H NMR (CDCl<highlight><subscript>3</subscript></highlight>, 200 MHz) &dgr;&equals;1.23 (s, 9H), 1.36 (d, 3H, J&equals;6.3 Hz), 2.3 (br s, 1H), 3.21 (dd, 1H, J&equals;2.2 and 6.3 Hz), 4.24 (dq, 1H, J&equals;6.3 and 6.3 Hz), 4.58 (d, 1H, J&equals;2.2 Hz), 6.47 (s, 1H); <highlight><superscript>13</superscript></highlight>C NMR (CDCl<highlight><subscript>3</subscript></highlight>, 50 MHz) &ngr;&equals;22.0, 26.6, 44.3, 52.6, 64.1, 65.9, 169.0, 213.0; Anal. calcd for C<highlight><subscript>10</subscript></highlight>H<highlight><subscript>17</subscript></highlight>O<highlight><subscript>3</subscript></highlight>N: C, 60.28; H, 8.60; N, 7.03&mdash;Found: C, 60.13; H, 8.70; N, 6.96%. </paragraph>
</section>
<section>
<heading lvl="1">Example 7 </heading>
</section>
<section>
<heading lvl="1">Conversion of (3S, 4S)-1-benzyhydryl-3-&lsqb;(5R)-1&prime;-(t-butyidimethylsilyloxy)ethyl&rsqb;-4-pivaloyl-2-azetidinone to (3S, 4S)-1-(diphenyl)hydroxymethyl-3-&lsqb;(5R)-1&prime;-(t-butyidimethylsilyloxy)ethyl&rsqb;-4-pivaloyl-2-azetidinone </heading>
<paragraph id="P-0090" lvl="0"><number>&lsqb;0090&rsqb;</number>  
<chemistry-cwu id="CHEM-US-00013">
<number>13</number>
<image id="EMI-C00013" he="193.2336" wi="216.027" file="US20030004335A1-20030102-C00013.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00013" file="US20030004335A1-20030102-C00013.CDX"/>
<chemistry-mol-file id="CHEMMOL-00013" file="US20030004335A1-20030102-C00013.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0091" lvl="7"><number>&lsqb;0091&rsqb;</number> A solution of (3S, 4S)-1-benzyhydryl-3-&lsqb;(5R)-1&prime;-(t-butyidimethylsilyloxy)ethyl&rsqb;-4-pivaloyl-2-azetidinone (0.13 g, 0.27 mmol) in wet chlorobenzene was treated with NBS under irradiation, as described in example 5, to furnish crude (3S, 4S)-1-(diphenyl)hydroxymethyl-3-&lsqb;(5R)-1&prime;-(t-butyldimethylsilyloxy)ethyl&rsqb;-4-pivaloyl-2-azetidinone as a pale yellow solid (0.11 g, 81% yield):<highlight><superscript>1</superscript></highlight>H NMR (CDCl<highlight><subscript>3, 200 </subscript></highlight>MHz) &dgr;&equals;0.15 (s, 3H), 0.16 (s, 3H), 0.80 (s, 9H), 0.96 (s, 9H), 1.33 (d, 3h, J&equals;6.3 Hz), 2.78 (dd, 1H, J&equals;6 and 2.2 Hz), 4.30 (m, 1H), 4.72 (d, 1H, J&equals;2.2 Hz), 5.18 (brs, 1H), 7.1-7.6 (m, 10H). </paragraph>
</section>
<section>
<heading lvl="1">Example 8 </heading>
</section>
<section>
<heading lvl="1">Conversion of (3S, 4S)-1-(diphenyl)hydroxymethyl-3-&lsqb;(5R)-1&prime;-(t-butyidimethylsilyloxy) ethyl&rsqb;-4-pivaloyl-2-azetidinone to (3S, 4S)-3-&lsqb;(5R)-1&prime;-(t-butyidimethylsilyloxy)ethyl&rsqb;-4-pivaloyl-2-azetidinone </heading>
<paragraph id="P-0092" lvl="0"><number>&lsqb;0092&rsqb;</number>  
<chemistry-cwu id="CHEM-US-00014">
<number>14</number>
<image id="EMI-C00014" he="160.3476" wi="216.027" file="US20030004335A1-20030102-C00014.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00014" file="US20030004335A1-20030102-C00014.CDX"/>
<chemistry-mol-file id="CHEMMOL-00014" file="US20030004335A1-20030102-C00014.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0093" lvl="7"><number>&lsqb;0093&rsqb;</number> A solution of (3S, 4S)-1-(diphenyl)hydroxymethyl-3-&lsqb;(5R)-1&prime;-(t-butyldimethylsilyloxy) ethyl&rsqb;-4-pivaloyl-2-azetidinone (0.11g, 0.22 mmol) in CH<highlight><subscript>3</subscript></highlight>CN&mdash;H<highlight><subscript>2</subscript></highlight>O was treated as described in example 6, to furnish (3S, 4S)-3-&lsqb;(5R)-1&prime;-(t-butyldimethylsilyloxy)ethyl&rsqb;-4-pivaloyl-2-azetidinone (0.066 g, 95% yield). This compound was identical to the product obtained in example 9. </paragraph>
</section>
<section>
<heading lvl="1">Example 9 </heading>
</section>
<section>
<heading lvl="1">Conversion of (3S, 4S)-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone to (3S, 4S)-3-&lsqb;(5R)-1&prime;-(t-butyidimethylsilyloxy)ethyl-4-pivaloyl-2-azetidinone </heading>
<paragraph id="P-0094" lvl="0"><number>&lsqb;0094&rsqb;</number>  
<chemistry-cwu id="CHEM-US-00015">
<number>15</number>
<image id="EMI-C00015" he="160.3476" wi="216.027" file="US20030004335A1-20030102-C00015.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00015" file="US20030004335A1-20030102-C00015.CDX"/>
<chemistry-mol-file id="CHEMMOL-00015" file="US20030004335A1-20030102-C00015.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0095" lvl="7"><number>&lsqb;0095&rsqb;</number> t-Butyldimethylsilyl chloride (2.04 g, 14 mmol) and imidazole (2.31 g, 34 mmol) were added to a solution of (3S, 4S)-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-pivaloyl-2-azetidinone (1.35 g, 6.8 mmol) in DMF (70 ml). The mixture was stirred, under argon atmosphere, at room temperature, during 16 h, then diluted with ethyl acetate (50 mL). The organic phase was washed with brine (3&times;50 mL). Drying over MgSO<highlight><subscript>4</subscript></highlight>, concentration and flash chromatography on silica gel (elution with CH<highlight><subscript>2</subscript></highlight>Cl<highlight><subscript>2</subscript></highlight>: EtOAc, 10:1; R<highlight><subscript>f</subscript></highlight>&equals;0.36) gave (3S, 4S)-3-&lsqb;(5R)-1&prime;-(t-butyidimethylsilyloxy)ethyl-4-pivaloyl-2-azetidinone as a white solid (1.47 g, 70% yield): IR (KBr) &ngr;&equals;3158, 2954,1767,1723,1472 cm<highlight><superscript>&minus;1</superscript></highlight>; <highlight><superscript>1</superscript></highlight>H NMR (CDCl<highlight><subscript>3</subscript></highlight>, 300 MHz) &dgr;&equals;0.09 and 0.10 (s, 6H), 0.89 (s, 9H), 1.22 (s, 9H), 1.26 (d, 3H, J&equals;6.3 Hz), 3.17 (m, 1H), 4.27 (dq, 1H, J&equals;6.3 and 4.5 Hz), 4.59 (d, 1H, J&equals;2.1 Hz), 5.96 (br s, 1H). </paragraph>
</section>
<section>
<heading lvl="1">Example 10 </heading>
</section>
<section>
<heading lvl="1">Conversion of (3S, 4S)-1-benzhydryl-3-&lsqb;(5R) -1&prime;-hydroxyethyl&rsqb;-4-benzoyl-2-azetidinone to (3S,4S)-3-&lsqb;(5R)-1&prime;-hydroxyethyl&rsqb;-4-benzoyl-2-azetidinone </heading>
<paragraph id="P-0096" lvl="0"><number>&lsqb;0096&rsqb;</number>  
<chemistry-cwu id="CHEM-US-00016">
<number>16</number>
<image id="EMI-C00016" he="75.83625" wi="213.39045" file="US20030004335A1-20030102-C00016.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00016" file="US20030004335A1-20030102-C00016.CDX"/>
<chemistry-mol-file id="CHEMMOL-00016" file="US20030004335A1-20030102-C00016.MOL"/>
</chemistry-cwu>
</paragraph>
<paragraph id="P-0097" lvl="7"><number>&lsqb;0097&rsqb;</number> A solution of (3S, 4S)-1-benzhydryl-3-&lsqb;(5R)-1&prime;-(t-butyidimethylsilyloxy)ethyl&rsqb;-4-benzoyl-2-azetidinone (0.11 g, 0.28 mmol) in wet chlorobenzene was treated with NBS under light, as described in example 5, to furnish crude (3S, 4S)-1-diphenylhydroxymethyl-3-&lsqb;(5R)-1&prime;-(t-butyldimethylsilyloxy)ethyl&rsqb;-4-benzoyl-2-azetidinone as a pale yellow oil. The product is then treated as described in example 6 in CH<highlight><subscript>3</subscript></highlight>CN&mdash;H<highlight><subscript>2</subscript></highlight>O with p-Tos OH to furnish (3S, 4S)-3-&lsqb;(5R)-1&prime;-(t-butyldimethylsilyloxy)ethyl&rsqb;-4-benzoyl-2-azetidinone (0.059 g, 95%). </paragraph>
<paragraph id="P-0098" lvl="0"><number>&lsqb;0098&rsqb;</number> <highlight><superscript>1</superscript></highlight>H NMR 1.34 (3H, d, 6.2 Hz); 3.25 (1H, dd, 2.6 Hz, 1.2 Hz); 4.30 (1H, m, 6.4 Hz); 5.07(1H, d, 2.6 Hz); 7.4-7.8 (3H, m); 8.11 (2H, d, 7.2 Hz). </paragraph>
<paragraph id="P-0099" lvl="0"><number>&lsqb;0099&rsqb;</number> The entire disclosure of all applications, patents and publications, cited herein and of corresponding European application No. 01870100.3, filed May 10, 2001, is incorporated by reference herein. </paragraph>
<paragraph id="P-0100" lvl="0"><number>&lsqb;0100&rsqb;</number> The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples. </paragraph>
<paragraph id="P-0101" lvl="0"><number>&lsqb;0101&rsqb;</number> From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. </paragraph>
</section>
</detailed-description>
</subdoc-description>
<subdoc-claims>
<claim id="CLM-00001">
<claim-text><highlight><bold>1</bold></highlight>. A method for the preparation of a compound of the general formula (I) wherein 
<claim-text>R<highlight><superscript>1 </superscript></highlight>and R<highlight><superscript>2 </superscript></highlight>each represent independently hydrogen, halogen, hydroxy, thiol, nitro, amino, carboxy, amino derivative, oxy derivative, thio derivative, alkyl, alkenyl, alkynyl, aryl, oxy derivative, amino derivative, thiol derivative, acyl derivative, acyloxy derivative, ester, amido, ether, arylalkyl, heterocycle or Me(OR&prime;)CH wherein R&prime; is hydrogen or R<highlight><superscript>a</superscript></highlight>R<highlight><superscript>b</superscript></highlight>R<highlight><superscript>c</superscript></highlight>Si wherein R<highlight><superscript>a</superscript></highlight>, R<highlight><superscript>b </superscript></highlight>and R<highlight><superscript>c </superscript></highlight>is independently chosen from the group consisting of alkyl, alkenyl, alkynyl, aryl or a heterocycle; </claim-text>
<claim-text>R<highlight><superscript>3 </superscript></highlight>represents a protecting group such as alkyl, alkenyl, alkynyl, or arylalkyl; wherein this method comprises the reaction of a compound of the general formula (II) in the presence of a halogen-radical source, water and a proton donor suitable as a catalyst, according to the following scheme. </claim-text>
<claim-text> 
<chemistry-cwu id="CHEM-US-00017">
<number>17</number>
<image id="EMI-C00017" he="58.5711" wi="150.255" file="US20030004335A1-20030102-C00017.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00017" file="US20030004335A1-20030102-C00017.CDX"/>
<chemistry-mol-file id="CHEMMOL-00017" file="US20030004335A1-20030102-C00017.MOL"/>
</chemistry-cwu>
</claim-text>
</claim-text>
</claim>
<claim id="CLM-00002">
<claim-text><highlight><bold>2</bold></highlight>. A method according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference> wherein R<highlight><superscript>1 </superscript></highlight>represents Me(OR&prime;)CH wherein R&prime; is hydrogen. </claim-text>
</claim>
<claim id="CLM-00003">
<claim-text><highlight><bold>3</bold></highlight>. A method according to <dependent-claim-reference depends_on="CLM-00001">claim 1</dependent-claim-reference> wherein R<highlight><superscript>1 </superscript></highlight>represents Me(OR&prime;)CH wherein R&prime; is R<highlight><superscript>a</superscript></highlight>R<highlight><superscript>b</superscript></highlight>R<highlight><superscript>c</superscript></highlight>Si wherein R<highlight><superscript>a</superscript></highlight>, R<highlight><superscript>b </superscript></highlight>and R<highlight><superscript>c </superscript></highlight>independently represent methyl, ethyl, i-Pr, t-butyl or phenyl. </claim-text>
</claim>
<claim id="CLM-00004">
<claim-text><highlight><bold>4</bold></highlight>. A method according to claims <highlight><bold>1</bold></highlight>-<highlight><bold>3</bold></highlight> wherein R<highlight><superscript>2 </superscript></highlight>represents an acyl derivative of the formula R&Prime;&mdash;CO&mdash; wherein R&Prime; is chosen from the group consisting of hydrogen, alkyl, substituted alkyl, preferably t-butyl, phenyl, substituted phenyl, OR<highlight><superscript>d </superscript></highlight>or SR<highlight><superscript>d </superscript></highlight>wherein R<highlight><superscript>d </superscript></highlight>is C<highlight><subscript>1-6 </subscript></highlight>alkyl, substituted alkyl, phenyl, substituted phenyl. </claim-text>
</claim>
<claim id="CLM-00005">
<claim-text><highlight><bold>5</bold></highlight>. A method according to claims <highlight><bold>1</bold></highlight>-<highlight><bold>4</bold></highlight> wherein R<highlight><superscript>3 </superscript></highlight>represents an arylalkyl, preferably methyl-bisphenyl or substituted methyl-bisphenyl. </claim-text>
</claim>
<claim id="CLM-00006">
<claim-text><highlight><bold>6</bold></highlight>. A method according to claims <highlight><bold>1</bold></highlight>-<highlight><bold>5</bold></highlight> wherein said halogen radical is provided from a N-halogeno compound selected from the group consisting of N-halogeno-amines, N-halogeno-amides, N-halogeno-imides, N-halogeno-ureas, N-halogeno-carbamates or N-halogeno-hydantoines. </claim-text>
</claim>
<claim id="CLM-00007">
<claim-text><highlight><bold>7</bold></highlight>. A method according to <dependent-claim-reference depends_on="CLM-00005">claim 5</dependent-claim-reference> wherein said halogen radical source is N-halogeno-succinimide, preferably N-bromosuccinimide. </claim-text>
</claim>
<claim id="CLM-00008">
<claim-text><highlight><bold>8</bold></highlight>. A method according to any of the claims <highlight><bold>1</bold></highlight>-<highlight><bold>7</bold></highlight> for the preparation of a compound of the general formula (I-A) wherein 
<claim-text>R&prime; is as noted in claims <highlight><bold>2</bold></highlight> or <highlight><bold>3</bold></highlight>, R&Prime; is as noted in <dependent-claim-reference depends_on="CLM-00004">claim 4</dependent-claim-reference>, and Y and Y&prime; are alkyl, alkyloxy, halogen or preferably hydrogen, </claim-text>
<claim-text>comprising the reaction of a compound of the general formula (II-B) in the presence of a halogen radical source, preferably N-bromosuccinimide (NBS) activated by light, and in the presence of water and a proton donor suitable as a catalyst, according to the following scheme. </claim-text>
<claim-text> 
<chemistry-cwu id="CHEM-US-00018">
<number>18</number>
<image id="EMI-C00018" he="207.8622" wi="216.027" file="US20030004335A1-20030102-C00018.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00018" file="US20030004335A1-20030102-C00018.CDX"/>
<chemistry-mol-file id="CHEMMOL-00018" file="US20030004335A1-20030102-C00018.MOL"/>
</chemistry-cwu>
</claim-text>
</claim-text>
</claim>
<claim id="CLM-00009">
<claim-text><highlight><bold>9</bold></highlight>. A method according to <dependent-claim-reference depends_on="CLM-00008">claim 8</dependent-claim-reference> for the preparation of a compound of the general formula (I-A) comprising the steps of 
<claim-text>(a) converting L-threonine to sodium (2S,3R)-cis-2,3-epoxybutanoate </claim-text>
<claim-text>(b) converting said sodium (2S,3R)-cis-2,3-epoxybutanoate to an epoxyamide of general formula (A), </claim-text>
<claim-text>(c) cyclization of said compound of general formula (A), into azetidinone (II-B) and </claim-text>
<claim-text>(d) removing the N-protecting group of the compound of the general formula (II-B) in the presence of a halogen radical source, preferably a halogen-containing nitrogen source, and more preferably N-bromosuccinimide and light, in the presence of water and a proton donor suitable as a catalyst, according to the following scheme: </claim-text>
<claim-text> 
<chemistry-cwu id="CHEM-US-00019">
<number>19</number>
<image id="EMI-C00019" he="506.47275" wi="216.027" file="US20030004335A1-20030102-C00019.TIF"/>
<chemistry-chemdraw-file id="CHEMCDX-00019" file="US20030004335A1-20030102-C00019.CDX"/>
<chemistry-mol-file id="CHEMMOL-00019" file="US20030004335A1-20030102-C00019.MOL"/>
</chemistry-cwu>
</claim-text>
</claim-text>
</claim>
<claim id="CLM-00010">
<claim-text><highlight><bold>10</bold></highlight>. A method according to <dependent-claim-reference depends_on="CLM-00009">claim 9</dependent-claim-reference> further optionally comprising a silanating step for the protection of the hydroxyl function when R&prime; is H performed either before or after the deprotecting step (d). </claim-text>
</claim>
<claim id="CLM-00011">
<claim-text><highlight><bold>11</bold></highlight>. A method according to any of claims <highlight><bold>1</bold></highlight>-<highlight><bold>10</bold></highlight> wherein said proton donor is selected from the group consisting of carboxylic acids, sulfonic acids and inorganic acids. </claim-text>
</claim>
<claim id="CLM-00012">
<claim-text><highlight><bold>12</bold></highlight>. A compound or intermediate obtainable by any of the methods according to claims <highlight><bold>1</bold></highlight>-<highlight><bold>11</bold></highlight>. </claim-text>
</claim>
<claim id="CLM-00013">
<claim-text><highlight><bold>13</bold></highlight>. A compound or intermediate obtained by any of the methods according to claims <highlight><bold>1</bold></highlight>-<highlight><bold>11</bold></highlight>. </claim-text>
</claim>
<claim id="CLM-00014">
<claim-text><highlight><bold>14</bold></highlight>. A compound of the general formula (I-A) wherein R&Prime; is t-butyl. </claim-text>
</claim>
<claim id="CLM-00015">
<claim-text><highlight><bold>15</bold></highlight>. A compound of the general formula (I-A) wherein R&prime; is R<highlight><superscript>a</superscript></highlight>R<highlight><superscript>b</superscript></highlight>R<highlight><superscript>c</superscript></highlight>Si wherein R<highlight><superscript>a</superscript></highlight>, R<highlight><superscript>b </superscript></highlight>and R<highlight><superscript>c </superscript></highlight>are as noted as in <dependent-claim-reference depends_on="CLM-00003">claim 3</dependent-claim-reference>. </claim-text>
</claim>
<claim id="CLM-00016">
<claim-text><highlight><bold>16</bold></highlight>. A pharmaceutically acceptable salt, geometrical isomer (including cis and trans, Z and E isomers), enantiomer, diastereoisomer or mixture (including racemates) of any compound according to any of claims <highlight><bold>12</bold></highlight>-<highlight><bold>15</bold></highlight>. </claim-text>
</claim>
<claim id="CLM-00017">
<claim-text><highlight><bold>17</bold></highlight>. Use of the method according to any of the claims <highlight><bold>1</bold></highlight>-<highlight><bold>11</bold></highlight> as an N-deprotection step in organic synthesis, and more preferably in peptide synthesis.</claim-text>
</claim>
</subdoc-claims>
</patent-application-publication>
